Organic turnover growth increases to 6.1%
Waregem (Belgium) / Rotterdam (the Netherlands)[1], 10 April 2012 – In the first quarter of 2012, the consolidated turnover of Arseus increased 17.7% to € 131.0 million. Organic growth was 6.1%.
The evolution of turnover[2] per division is as follows
Ger van Jeveren, CEO of Arseus: “Arseus had a good start of 2012 with turnover growth of 17.7% and organic turnover growth of no less than 6.1%. Arseus Dental’s result especially deserves a compliment. After a number of difficult years, organic turnover growth of 5% was realised in the first quarter. This was mainly due to structurally improved internal and operational processes at Arseus Dental Solutions. The strong organic turnover growth at Corilus was due to the further consolidation of market leadership and the continuous development and launch of new software solutions for medical professionals. The successful introduction of new medical products and concepts at Arseus Medical was not enough to fully compensate for the effects of phasing out a number of non-strategic distributions in the second half of 2011. As it has for the past 22 years, Fagron continues to achieve success in revitalising pharmaceutical compounding and will further consolidate its worldwide market leadership in 2012 as well via an active buy-and-build strategy, starting up greenfields and robust organic growth.
We look to the future with confidence and consequently confirm the expectations for 2012 that we announced earlier.”
[1] This press release was sent out by Arseus NV and Arseus BV.
[2] Unaudited management figures.
Please open the link below for the full press release: